FDA Approves Targeted Radiotherapy for Neuroendocrine Tumors

The U.S. Food and Drug Administration (FDA) recently added a new therapeutic to the armamentarium for oncologists treating patients with neuroendocrine tumors. The new therapeutic—lutetium (Lu) 177 dotatate (Lutathera)—is a targeted form of systemic radiotherapy.

Read More

World Cancer Day: Get the Facts

The American Association for Cancer Research (AACR) is proud to support World Cancer Day, a yearly initiative of the Union for International Cancer Control (UICC). Each February 4, World Cancer Day serves as a rallying cry to raise awareness of the global battle against cancer and of the need for government leaders to make cancer research, prevention, and treatment a national priority.

Read More

FDA Approves First Targeted Therapeutic for BRCA-mutant Breast Cancer

On Friday, the U.S. Food and Drug Administration (FDA) approved the molecularly targeted therapeutic olaparib (Lynparza) for treating certain patients with metastatic, HER2-negative breast cancer. The FDA also granted marketing authorization for a test to identify those patients eligible to receive olaparib: patients with an inherited, cancer-associated BRCA1 or BRCA2 (BRCA1/2) mutation.

Read More

Biosimilars: Breaking Through to Cancer Treatment

A little-talked-about provision of the 2010 Patient Protection and Affordable Care Act designed to improve access to innovative medical therapies has recently borne fruit for the cancer community in the form of two new therapeutic options for a wide range of cancers—bevacizumab-awwb (Mvasi) and trastuzumab-dkst (Ogivri).

Read More

Holding Tobacco Companies Accountable for Deceptive Ads

The relationship between cigarette smoking and lung cancer was first brought to the public’s attention more than 50 years ago, when the U.S. Surgeon General’s report on “Smoking and Health” was published. However, tobacco companies are only now telling the truth about their deadly products, and only thanks to a 2006 court order that they spent more than a decade trying to overturn.

Read More

Vemurafenib Becomes First FDA-approved Treatment for a Rare Type of Blood Cancer

Recently, the U.S. Food and Drug Administration (FDA) approved the molecularly targeted therapeutic vemurafenib (Zelboraf) for treating certain adults who have a rare type of blood cancer called Erdheim-Chester disease. Vemurafenib targets mutant forms of the protein BRAF, and it has been approved for treating those patients whose Erdheim-Chester disease harbors the BRAF V600 mutation.

Read More

Advances in Tobacco Control

Cigarette smoking is the leading cause of death from lung cancer in the United States. That’s why November, Lung Cancer Awareness Month, is a good time to highlight new advances in tobacco control, such as the legislation that came into effect Nov. 1, 2017, in New Jersey that raises the minimum age of legal access to tobacco products to 21.

Read More